mdma
A recent study published in the European Journal of Neuroscience provides new insights into how 3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy or molly, affects the brain’s processing of emotional stimuli. Researchers found that MDMA significantly altered the brain’s response to emotional faces, shedding light on the drug’s unique impact on social and emotional processing. MDMA is known for its recreational use due to its euphoric and empathogenic effects. It is also under investigation as a potential treatment for post-traumatic stress disorder (PTSD) when combined with p...
PsyPost (CA)
A recent study published in the European Journal of Neuroscience provides new insights into how 3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy or molly, affects the brain’s processing of emotional stimuli. Researchers found that MDMA significantly altered the brain’s response to emotional faces, shedding light on the drug’s unique impact on social and emotional processing. MDMA is known for its recreational use due to its euphoric and empathogenic effects. It is also under investigation as a potential treatment for post-traumatic stress disorder (PTSD) when combined with p...
PsyPost
A recent study published in the European Journal of Neuroscience provides new insights into how 3,4-methylenedioxymethamphetamine (MDMA), commonly known as ecstasy or molly, affects the brain’s processing of emotional stimuli. Researchers found that MDMA significantly altered the brain’s response to emotional faces, shedding light on the drug’s unique impact on social and emotional processing. MDMA is known for its recreational use due to its euphoric and empathogenic effects. It is also under investigation as a potential treatment for post-traumatic stress disorder (PTSD) when combined with p...
PsyPost (UK)
Efforts to make MDMA legally available as a psychotherapeutic catalyst hit a daunting roadblock on Tuesday when an expert panel overwhelmingly voted to recommend that the Food and Drug Administration (FDA) reject a new drug application that Lykos Therapeutics submitted in February. Members of the panel expressed several concerns about two Phase 3 studies of MDMA's safety and effectiveness in treating post-traumatic stress disorder (PTSD), including unblinding of subjects, potential underreporting of adverse events, and allegedly inadequate assessment of MDMA's abuse potential. "We are disappoi...
Reason
Washington (AFP) - A panel of US health experts convened by the Food and Drug Administration on Tuesday overwhelmingly voted against the use of MDMA, commonly known as ecstasy, to treat post-traumatic stress disorder. PTSD, a debilitating mental health condition that develops after a person experiences or is threatened by traumatic events such as death, combat or sexual assault, affects an estimated five percent of Americans in any given year. But pharmaceutical treatment options are so far limited to two antidepressants that require three months of dosing to take effect, and response rates t...
AFP
Washington (AFP) - A panel of US health experts convened by the Food and Drug Administration (FDA) are meeting Tuesday to weigh the benefits and risks of using MDMA, commonly known as ecstasy, to treat post-traumatic stress disorder. PTSD, a debilitating mental health condition that develops after a person experiences or is threatened by traumatic events such as death, combat, or sexual assault, affects an estimated five percent of Americans in any given year. But treatment options are so far limited to two antidepressants that require three months of dosing to take effect, and response rates...
AFP
A recent case study published in Clinical Case Reports describes the journey of a 41-year-old woman who turned to psilocybin and MDMA to manage her debilitating post-COVID symptoms. The paper raises the intriguing possibility, which is far from certain, that psychedelic substances might help alleviate the psychological and cognitive symptoms associated with Long-COVID. Long-COVID, also known as post-acute sequelae of SARS-CoV-2 infection, encompasses a range of symptoms that persist well beyond the initial recovery from COVID-19. These symptoms can include fatigue, cognitive impairment, anxiet...
PsyPost
A recent case study published in Clinical Case Reports describes the journey of a 41-year-old woman who turned to psilocybin and MDMA to manage her debilitating post-COVID symptoms. The paper raises the intriguing possibility, which is far from certain, that psychedelic substances might help alleviate the psychological and cognitive symptoms associated with Long-COVID. Long-COVID, also known as post-acute sequelae of SARS-CoV-2 infection, encompasses a range of symptoms that persist well beyond the initial recovery from COVID-19. These symptoms can include fatigue, cognitive impairment, anxiet...
PsyPost (UK)
A recent case study published in Clinical Case Reports describes the journey of a 41-year-old woman who turned to psilocybin and MDMA to manage her debilitating post-COVID symptoms. The paper raises the intriguing possibility, which is far from certain, that psychedelic substances might help alleviate the psychological and cognitive symptoms associated with Long-COVID. Long-COVID, also known as post-acute sequelae of SARS-CoV-2 infection, encompasses a range of symptoms that persist well beyond the initial recovery from COVID-19. These symptoms can include fatigue, cognitive impairment, anxiet...
PsyPost (CA)
Interviews conducted with two clinicians specializing in treating patients with borderline personality disorder and two providing MDMA-assisted therapy primarily for individuals with Post-Traumatic Stress Disorder (PTSD) have yielded insights into the similarities between these disorders. Based on this, the authors of the research suggest that the potential benefits of MDMA in treating borderline personality disorder warrant further detailed exploration. The paper was published in Journal of Psychedelic Studies. Borderline personality disorder is a complex and often debilitating mental health ...
PsyPost
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら